Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Journal of Experimental & Clinical Cancer Research volume 41, Article number: 138 (2022)
Correction to: J Exp Clin Cancer Res 41, 83 (2022)
The corrected figures are given here.
In the Reagents section of the Materials and Methods, the second sentence originally contained a typo. The antibody name was listed as ‘poly-(ADPribose)-Polymerase (PARP)-Ab (#556494)’; the ‘-Ab’ was included in error. The correct sentence therefore reads:
Primary antibodies for western blotting were used according to the manufacturer’s protocol: β-Actin (#8227), poly-(ADPribose)-Polymerase (PARP) (#556494), phospho-Histone H2AX (γH2AX) (#05636), FOXM1 (#5436S), β-catenin (#8480S), Oct-4 (#2750S), were purchased from Cell signaling Technology (Danvers, MA, USA). γ-Tubulin (#sc-7396) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
In addition, in the caption for Fig. 6a-b, the description should read as follows (emphasis placed on adjusted wording, which originally said ‘(GT)’:
A-B. PANC28 and PANC1 cells were s.c. injected into athymic mice as described in the Materials and Methods. When established tumors were palpable, mice were treated with vehicles or domatinostat (20 mg/Kg 5 days/week, per os) alone and in combination with gemcitabine (weekly 25 mg/Kg, i.p.) and abraxane (weekly 20 mg/Kg, i.p.) (GemNP) for two weeks.
In the Availability of data and materials section, it has been updated to: All data generated or analyzed during this study are included in this published article or in supplementary information. Materials, additional data, and protocols described in the manuscript will be made available from the corresponding authors upon reasonable request. Raw data are available at https://doi.org/10.6084/m9.figshare.19368845.
The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.
Roca MS, Moccia T, Iannelli F, et al. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. J Exp Clin Cancer Res. 2022;41:83 https://doi.org/10.1186/s13046-022-02295-4.
About this article
Cite this article
Roca, M.S., Moccia, T., Iannelli, F. et al. Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. J Exp Clin Cancer Res 41, 138 (2022). https://doi.org/10.1186/s13046-022-02324-2